CAMPTOSAR vs VITRAKVI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 16, 2026·How we rate

Possible drug interaction. CAMPTOSAR and VITRAKVI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CAMPTOSAR	VITRAKVI
Rating	64/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	IRINOTECAN HYDROCHLORIDE	LAROTRECTINIB SULFATE
Manufacturer	Pfizer	Bayer Hlthcare
Dosage forms	Injectable	Capsule, Solution
Drug class	Topoisomerase Inhibitor	—
Boxed warning	Boxed warning	None
Treats	Breast Neoplasms, Non-Small-Cell Lung Carcinoma, Colonic Neoplasms	Neoplasm Metastasis

camptosar vitrakvi

Rating

64/100

New

Pharmacy pays

—

Type

Active ingredient

IRINOTECAN HYDROCHLORIDE

LAROTRECTINIB SULFATE

Manufacturer

Pfizer

Bayer Hlthcare

Dosage forms

Injectable

Capsule, Solution

Drug class

Topoisomerase Inhibitor

—

Boxed warning

None

Treats

Breast Neoplasms, Non-Small-Cell Lung Carcinoma, Colonic Neoplasms

Neoplasm Metastasis

Frequently asked questions

What is the difference between Camptosar and Vitrakvi?

Camptosar contains Irinotecan Hydrochloride, while Vitrakvi contains Larotrectinib Sulfate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.